TB Vax ARM

Three wins needed to deliver new TB vaccines this decade

The TB Vax ARM outlines three key advocacy wins for the field to achieve by 2026 in order to effectively advance TB vaccine development. Check them out and sign a petition to show your support!

Read More →

TB Vax ARM meeting: Setting the scene for TB R&D advocacy in 2024

The TB Vaccine Advocacy Roadmap (TB Vax ARM) will hold its first virtual meeting of the year on 14 February 2024 with updates on key news and developments from the field from Treatment Action Group, FIND, and IAVI:

Read More →

TB Vax ARM: What's next for TB R&D post-HLM? A pre-Union virtual meeting

In preparation for the Union World Conference on Lung Health in Paris, France on 15-18 November 2023, the TB Vaccine Advocacy Roadmap (TB Vax ARM) will host a virtual meeting on 2 November 2023 exploring what’s next for TB research and development (R&D) following the United Nations High-Level Meeting on TB (HLM).

Read More →

TB Vax ARM virtual meeting: Prioritizing TB R&D at the UNHLM on TB and beyond

With the United Nations High-Level Meeting (UNHLM) on TB just weeks away, the TB Vaccine Advocacy Roadmap (TB Vax ARM) will host a special meeting on TB research and development (R&D) advocacy in the run up to this milestone event.

Read More →

Member States must commit to invest in TB vaccine R&D

A one-pager, developed by TB Vax ARM, provides relevant background information on the critical need for Member States to substantially increase adequate, predictable, and sustainable financing for TB vaccine research.

Read More →

Act now: A call to world leaders to increase investment in TB vaccine R&D

Global TB community calls on world leaders to increase political and financial commitments to develop and roll out new TB vaccines as a central part of the global TB response.

Read More →

New TB vaccines needed to tackle AMR

Tuberculosis (TB) is an airborne global pandemic that kills 1.6 million people each year, causes over 10 million people to fall sick, and poses catastrophic costs for patients and rising costs for health systems. The growing threat of drug-resistant TB is a major contributor to the global burden of antimicrobial resistance (AMR) and a significant cause of AMR deaths. New vaccines are urgently needed to tackle this crisis. Yet, despite the huge threat posed by drug-resistant TB, political and financial support falls dangerously short of what is needed to effectively address this threat.

Read More →

TB vaccine advocacy fellowship 2023 - APPLY NOW

The TB Vaccine Advocacy Roadmap (TB Vax ARM) and the Stop TB Partnership Working Group on New TB Vaccines announced a new advocacy fellowship program, set to take place in February 2023 in the run up to World TB Day. The program will convene six fellows representing TB affected communities, advocates, and early career researchers from high TB burden countries for an online skill building and co-learning program. The goal of the program is to help cultivate a new generation of TB vaccine R&D advocates and stimulate more diverse advocacy efforts for TB vaccine R&D ahead of the UN High-Level Meeting on TB in September 2023 and beyond.

Read More →

Advocates call on European leadership to fulfil their commitment to new TB vaccines

TB Vax ARM launches a campaign calling on the European leadership to fulfil their political and funding commitment to deliver new vaccines to end TB by 2030.

Read More →

TB survivors call on G20 to invest in new TB vaccines

TB Vax ARM launches a campaign calling on G20 governments to fulfil their funding and political commitments to develop new TB vaccines.

Read More →

Page 1 of 1 · Total posts: 10

1